Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Precision treatment improves outcomes in HR+/HER2− breast cancer subtypes by tailoring therapy based on characteristics.
• Distinct SNF subtypes of HR+/HER2− breast cancer show varying clinicopathologic profiles, supporting personalized treatment strategies.
• The analysis of early-stage, real-world cohorts highlights the potential of subtyping in enhancing therapeutic efficacy.
• This research underscores the need for targeted treatment approaches rather than traditional one-size-fits-all therapy.